SVA SINOVAC BIOTECH LTD Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1084201 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY6.8%
TTM net income YoY-165.7%
TTM EPS YoY-165.4%
Revenue 3-yr CAGR-36.0%
Net income 3-yr CAGR—
Margins
Gross margin67.9%
Operating margin-127.0%
Net margin-15.5%
FCF margin-145.4%
EBITDA margin-101.7%
Returns
ROE-0.9%
ROA-0.6%
ROIC (approx.)-6.1%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets25.1%
Debt / equity0.11x
Current ratio4.59x
Interest coverage-49.92x
Cash quality & payout
Operating cash flow / net income8.58x
Accruals ratio4.3%
Payout ratio—
Capex / revenue12.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $386.01M | $361.37M |
| Cost of revenue | $124.03M | $140.69M |
| Gross profit | $261.98M | $220.69M |
| R&D expense | $216.18M | $270.66M |
| SG&A expense | $332.98M | $420.92M |
| Operating income | -$490.13M | -$505.54M |
| Interest expense | $9.82M | $5.64M |
| Pretax income | -$262.10M | $42.84M |
| Income tax | -$63.27M | $2.18M |
| Net income | -$59.68M | $90.91M |
| EBITDA | -$392.68M | -$395.31M |
| EPS (basic) | -0.83 | 1.27 |
| EPS (diluted) | -0.83 | 1.27 |
| Dividends declared per share | 55.00 | — |
| Weighted avg. shares (diluted) | 71.86M | 71.86M |
| Balance sheet | ||
| Cash & equivalents | $488.25M | $335.27M |
| Short-term investments | $5.48B | $9.61B |
| Receivables | $286.34M | $300.89M |
| Inventory | $94.31M | $96.92M |
| Current assets | $7.06B | $10.64B |
| PP&E, net | $706.06M | $880.97M |
| Goodwill | $12.60M | $27.51M |
| Intangibles | $77.68M | $122.58M |
| Total assets | $8.54B | $12.34B |
| Current liabilities | $1.54B | $1.45B |
| Long-term debt | $494.86M | $375.76M |
| Total debt | $494.86M | $375.76M |
| Total liabilities | $2.15B | $2.04B |
| Shareholders' equity | $4.44B | $8.26B |
| Net debt | $6.61M | $40.49M |
| Shares outstanding | 71.86M | 71.86M |
| Cash flow statement | ||
| Operating cash flow | -$512.18M | -$56.89M |
| Capital expenditure | $48.92M | $95.96M |
| Free cash flow | -$561.10M | -$152.85M |
| Investing cash flow | $4.39B | $456.36M |
| Financing cash flow | -$3.43B | -$823.95M |
| Depreciation & amortization | $97.45M | $110.23M |
| Stock-based compensation | $0 | $0 |
| Dividends paid | $3.53B | $947.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.